Becton Dickinson stock gains as guidance and dividend underpin valuation

Published on 09/15/2026 at 22:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Becton Dickinson stock closed at USD 181.59 on the NYSE on September 14, 2026, up 2.1 percent from the prior close in a weak market. Analysts see FY 2026 EPS around USD 12.67 with a quarterly dividend of USD 1.05 per share supporting income-focused investors.

Steriler Reinraum mit Mitarbeitern an der Produktionslinie für Medizinprodukte — Becton Dickinson betreibt moderne Reinraum Fertigungsanlagen für Medizinprodukte weltweit, ISIN US0718131099 NYSE, Illustration mit AI erstellt.

Becton, Dickinson and Company stock (ISIN US0718131099) closed at USD 181.59 on the NYSE on September 14, 2026, marking a 2.1 percent gain versus the previous close of USD 177.85 in a session where the S&P 500 fell 0.5 percent to 7,619.98.

Stock moves higher on recent session

According to an equity overview published on September 15, 2026, Becton Dickinson stock finished the last trading session at USD 181.59 on the NYSE compared with a prior close of USD 177.85, translating into a 2.1 percent rise on September 14, 2026.Ad-hoc-news The same overview notes an intraday trading range between an approximate low of USD 177.75 and a high near USD 182.10, placing the closing price toward the upper end of the day’s band on September 14, 2026.Ad-hoc-news In the same session the S&P 500 index declined 0.5 percent to 7,619.98, which means Becton Dickinson outperformed the broader US equity benchmark despite the index weakness.Ad-hoc-news

Earnings outlook and guidance frame valuation

For the quarter ending September 2026, the Zacks Consensus Estimate for Becton Dickinson stands at USD 4.06 earnings per share, with the estimate dated for a report expected around November 5, 2026.Zacks In the most recently reported quarter, the company delivered earnings of USD 3.23 per share, beating the Zacks Consensus Estimate of USD 3.14 per share and resulting in a positive earnings surprise of 2.87 percent, which underlines management’s ability to meet or modestly exceed analyst expectations.Zacks On a full-year basis, Becton Dickinson has set its fiscal year 2026 guidance at an earnings per share range of USD 12.62 to USD 12.72, and the average analyst forecast currently sits at about USD 12.67 per share for the current year, indicating that the consensus view is aligned with company guidance.MarketBeat

Analyst consensus compiled by MarketBeat currently characterizes Becton Dickinson stock as a Hold, with an average price target of USD 187.67.MarketBeat Compared with the recent closing price of USD 181.59 on September 14, 2026, this average target implies room for upside of around USD 6 on the stock if the consensus materializes, which is a modest but tangible potential gain for investors focused on steady total return.

Dividend and capital allocation support income profile

The same MarketBeat overview notes that Becton Dickinson recently declared a quarterly dividend of USD 1.05 per share, to be paid on September 30, 2026, to investors of record on September 9, 2026, with an ex-dividend date also on September 9, 2026.MarketBeat On an annualized basis this dividend amounts to USD 4.20 per share, which corresponds to a yield of about 2.3 percent on the stock and provides a recurring income component on top of any capital appreciation.MarketBeat The payout ratio is reported at about 126.51 percent, which suggests that the dividend currently exceeds reported earnings and could be a focal point for investors when assessing the sustainability of distributions versus reinvestment in growth and debt reduction.MarketBeat

Operational initiatives and market capitalization context

Beyond earnings and dividends, Becton Dickinson continues to invest in its portfolio of medical technologies. A Zacks commentary dated September 15, 2026 highlights that the company is deploying its Vmax 160 system to advance intelligent pharmacy automation, pointing to ongoing efforts to improve medication management workflows in hospital and health-system environments.Zacks In the same piece, Zacks cites a current market capitalization for Becton Dickinson of approximately USD 49,000,000,000, underscoring its position as a large-cap player in the medical instruments and supplies segment.Zacks For investors, this scale can matter because it often correlates with diversified revenue streams and resilience across cycles, though it may also temper the pace at which earnings can grow relative to smaller, more focused peers.

Risk factors also feature in the current landscape. A notice published on September 15, 2026 by JND Legal Administration describes the Becton Fair Fund, which is now accepting claims from investors who purchased Becton Dickinson common stock between February 5, 2019 and February 5, 2020 and suffered losses, with a claims bar date set for December 13, 2026.PRNewswire While the relevant period and alleged issues date back several years, the ongoing fair-fund process can still influence sentiment and represents a reminder that legal and regulatory matters remain part of the broader risk profile for the stock.

Stock level and investor takeaway

As of the close on September 14, 2026, Becton Dickinson stock traded at USD 181.59 on the NYSE in USD, with the price sitting below the average analyst target of USD 187.67 but supported by fiscal year 2026 earnings guidance in the USD 12.62 to USD 12.72 per-share range and an annualized dividend of USD 4.20 per share yielding about 2.3 percent.